CHASITY FISHER: Open Payments
NPI 1720661762 · DOTHAN, AL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,635 in 133 payments from 20 companies in 2025. Trend: 2023 $2,090 · 2024 $2,172 · 2025 $2,635
Food & beverage: $2,617Education: $17
| Company | Payments | Amount |
|---|---|---|
| GlaxoSmithKline, LLC. | 25 | $429 |
| AstraZeneca Pharmaceuticals LP | 19 | $419 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 13 | $284 |
| Regeneron Healthcare Solutions, Inc. | 11 | $229 |
| Takeda Pharmaceuticals U.S.A., Inc. | 12 | $227 |
| Amgen Inc. | 11 | $173 |
| GENZYME CORPORATION | 7 | $169 |
| United Therapeutics Corporation | 7 | $162 |
| Verona Pharma, Inc. | 6 | $112 |
| Grifols USA, LLC | 3 | $90 |
Products named: DUPIXENT, TEZSPIRE, TRELEGY ELLIPTA, Tyvaso, NUCALA, GLASSIA, FASENRA, Ohtuvayre.
Industry payments across AL — which companies pay providers there.
